Coriolis Pharma to Invest $10M in New North Carolina R&D Facility

• Coriolis Pharma will invest $10 million to open a 13,000-square-foot research laboratory at Spark LS in Morrisville, North Carolina.

• The facility, set to open in Q1 2026, will create 50 jobs and support the company’s North American expansion.

Coriolis Pharma, a Contract Research and Development Organization (CRDO) specialising in formulation research for biopharmaceuticals, has announced a $10 million investment to establish its first U.S. laboratory in Morrisville, North Carolina. The new site will form part of the Spark LS life science campus and is expected to begin operations in the first quarter of 2026.

The 13,000-square-foot facility will focus initially on core services such as particle identification, before expanding to formulation development and lyophilization. These capabilities will be integrated with Coriolis Pharma’s global network, including its headquarters in Germany, to ensure scientific continuity across regions.

The investment marks a strategic milestone in the company’s North American growth plans and aligns with its broader mission to support biopharmaceutical innovation. “With our future presence in North Carolina, we will be able to serve our North American clients even better,” said Silvia Steyrer-Gruber, CEO of Coriolis Pharma.

Spark LS, where the lab will be housed, is a 108-acre innovation campus near Research Triangle Park, designed to support research, development, and manufacturing. It provides access to laboratory and biomanufacturing infrastructure alongside collaborative and recreational amenities.

By establishing this site, Coriolis Pharma is enhancing its commitment to the pharmaceutical and biotech sector through advanced digital and in-silico technologies, aimed at accelerating and de-risking drug development. The move also reinforces the role of North Carolina as a growing hub for global life science investment.